drugset / Trial / NCT00003568
Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
RandomizedTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with interleukin-2 in treating patients with metastatic melanoma.
Timeline
- Start
- 1998-11
- Primary completion
- —
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Intravenous |
| Subject | gp100 antigen | Peptide | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |